Description: <p><b>Matrine</b> — a naturally occurring tetracyclic quinolizidine alkaloid found predominantly in <i>Sophora flavescens</i> and related <i>Sophora</i> species, including <i>Sophora tonkinensis</i>. It is a plant-derived bioactive small molecule rather than an approved anticancer drug. Common abbreviations include Mat and MT. Matrine has broad anti-inflammatory, antifibrotic, neuroprotective and preclinical anticancer activities. Cancer studies consistently identify apoptosis, PI3K/AKT/mTOR suppression, Wnt/β-catenin inhibition, metabolic suppression, inhibition of invasion/EMT and context-dependent ROS-mediated cell death as important actions. More recent work also supports ferroptosis through pathways involving GPX4 and β-catenin/TCF7L2. Matrine should be distinguished from oxymatrine and from Compound Kushen Injection, which contains multiple constituents and has substantially more human clinical data.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of programmed cancer-cell death, particularly mitochondrial/caspase-dependent apoptosis through ↓ Bcl-2/Bax ratio, ↑ caspase-3/9 activity and suppression of survival proteins.</li>
<li>Suppression of PI3K/AKT/mTOR signaling, reducing cancer-cell survival, proliferation and growth while contributing to apoptosis and autophagy.</li>
<li>Suppression of Wnt/β-catenin signaling, including direct disruption of β-catenin/TCF7L2 signaling in some models, thereby reducing proliferation, metastasis and GPX4-mediated ferroptosis resistance.</li>
<li>Suppression of tumor glycolysis and the Warburg phenotype through targets including HK2 and, in recent TNBC work, ENO1-associated glycolytic enzyme complexes.</li>
<li>Inhibition of EMT, migration, invasion and metastasis through modulation of PTEN/AKT, β-catenin, E-cadherin, vimentin, MMP-2 and MMP-9.</li>
<li>Induction of ROS-mediated stress signaling in susceptible cancer cells; ROS can activate p38 and contribute to apoptosis, autophagy and ferroptosis. This effect is strongly model- and concentration-dependent.</li>
<li>Induction of ferroptosis in selected cancer models through ↓ GPX4, ↑ lipid peroxidation and, depending on tumor type, Piezo1/Ca²⁺ or β-catenin/TCF7L2 signaling.</li>
<li>Anti-angiogenic activity through suppression of VEGF/VEGFR signaling.</li>
<li>Chemosensitization in preclinical models, including increased cisplatin sensitivity through suppression of glycolysis/lactylation and DNA-repair-associated resistance mechanisms.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral matrine has relatively unfavorable and formulation-dependent pharmacokinetics. Rat studies report absolute oral bioavailability of approximately 17%, although botanical matrices can substantially alter absorption and disposition. A small human pharmacokinetic study using a multi-component botanical preparation detected systemic matrine and reported an approximately 10-hour plasma terminal half-life, but this cannot be directly extrapolated to purified matrine dosing. Low oral exposure, rapid disposition in several animal studies and toxicity are important constraints motivating nanoparticle, liposomal and other delivery approaches.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many cancer-cell studies use matrine in the high-micromolar to millimolar range, frequently approximately 0.1–2 mM or higher. These concentrations are substantially above exposures that can confidently be assumed achievable following conventional oral administration. Consequently, direct translation of many in-vitro anticancer effects to oral supplementation is uncertain. Newer studies identifying direct targets at lower concentrations improve mechanistic credibility but do not yet establish a clinically achievable anticancer exposure.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical for purified matrine as an anticancer agent. Cell-culture and animal xenograft evidence is extensive, but there is no established Phase I/II oncology development program demonstrating efficacy of purified matrine. Human randomized evidence frequently cited for “matrine” actually concerns Compound Kushen Injection, a multi-component <i>Sophora flavescens</i>-based preparation used adjunctively with chemotherapy in China; those results cannot be attributed specifically to matrine. Matrine is therefore best classified as a preclinical/investigational anticancer compound rather than an established adjunct cancer therapy. Hepatotoxicity and neurotoxicity are important dose-limiting safety concerns.</p>
<h3>Matrine Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Apoptosis / Bcl-2 / Bax / Caspases</td>
<td>↓ Bcl-2/Bax; ↑ Bax; ↑ caspase-3/9; ↑ apoptosis</td>
<td>Lower cytotoxicity reported in some comparative cell models</td>
<td>Programmed tumor-cell death</td>
<td>One of the most reproducible matrine anticancer phenotypes across tumor types.</td>
</tr>
<tr>
<td>2</td>
<td>PI3K / AKT / mTOR</td>
<td>↓ PI3K; ↓ p-AKT; ↓ mTOR signaling</td>
<td>Context-dependent</td>
<td>↓ survival and proliferation; ↑ apoptosis/autophagy</td>
<td>Central signaling axis supported in lung, breast, liver and other cancer models.</td>
</tr>
<tr>
<td>3</td>
<td>Wnt / β-catenin / TCF7L2</td>
<td>↓ β-catenin signaling; ↓ β-catenin/TCF7L2 complex</td>
<td>Not adequately characterized</td>
<td>↓ proliferation and metastasis; ↑ ferroptosis</td>
<td>Recent evidence supports β-catenin as a direct matrine target in TNBC; inhibition can reduce GPX4 transcription.</td>
</tr>
<tr>
<td>4</td>
<td>Glycolysis / Warburg Effect / HK2 / ENO1</td>
<td>↓ HK2; ↓ ENO1-associated glycolytic complex; ↓ glycolytic flux; ↓ lactylation</td>
<td>Not adequately characterized</td>
<td>Metabolic suppression and apoptosis</td>
<td>HK2 suppression is established in myeloid leukemia. Recent TNBC evidence identifies ENO1 as a direct target relevant to cisplatin resistance.</td>
</tr>
<tr>
<td>5</td>
<td>EMT / PTEN / AKT / MMP-2 / MMP-9</td>
<td>↑ PTEN; ↓ AKT; ↑ E-cadherin; ↓ vimentin; ↓ MMP-2/9</td>
<td>Not adequately characterized</td>
<td>↓ migration, invasion and metastasis</td>
<td>Supported across breast, hepatocellular, cervical and colorectal cancer models.</td>
</tr>
<tr>
<td>6</td>
<td>Ferroptosis / GPX4 / Lipid Peroxidation</td>
<td>↓ GPX4; ↑ Fe²⁺; ↑ lipid ROS; ↑ ferroptosis</td>
<td>Uncertain</td>
<td>Iron-dependent cancer-cell death</td>
<td>Demonstrated in cervical cancer and TNBC models. Mechanism is tumor-context dependent.</td>
</tr>
<tr>
<td>7</td>
<td>ROS / p38 Stress Signaling</td>
<td>↑ ROS; ↑ p38 activation; ↑ apoptosis</td>
<td>Variable; antioxidant effects reported in non-cancer disease models</td>
<td>Oxidative-stress-mediated cell death</td>
<td>ROS scavenging with NAC can attenuate matrine-induced apoptosis in susceptible cancer models. ROS direction is highly context-dependent outside cancer.</td>
</tr>
<tr>
<td>8</td>
<td>Ca²⁺ / Piezo1 / Ferroptosis</td>
<td>↑ Piezo1; ↑ Ca²⁺ influx; ↑ lipid peroxidation; ↑ ferroptosis</td>
<td>Not established</td>
<td>Ferroptotic cell death</td>
<td>Mechanistically demonstrated in cervical cancer; should be considered a contextual rather than universal matrine mechanism.</td>
</tr>
<tr>
<td>9</td>
<td>Autophagy / AMPK / AKT / mTOR</td>
<td>↑ LC3-II; ↑ Beclin-1; ↓ p62; ↑ autophagy</td>
<td>Context-dependent</td>
<td>Stress response and tumor growth inhibition</td>
<td>Autophagy may contribute to or oppose apoptosis depending on model and treatment conditions.</td>
</tr>
<tr>
<td>10</td>
<td>VEGF / VEGFR Angiogenesis</td>
<td>↓ VEGF; ↓ VEGFR signaling; ↓ microvessel density</td>
<td>Not adequately characterized</td>
<td>↓ tumor angiogenesis</td>
<td>Observed in breast-cancer xenografts and linked with AKT/NF-κB and Wnt/β-catenin modulation.</td>
</tr>
<tr>
<td>11</td>
<td>NF-κB Signaling</td>
<td>Usually ↓ IKKβ / NF-κB activity; context-dependent activation also reported</td>
<td>Context-dependent</td>
<td>↓ survival, inflammation and invasion</td>
<td>Direction is not uniform. In HepG2 cells matrine-induced NF-κB activation appeared protective because NF-κB inhibition increased matrine-induced apoptosis.</td>
</tr>
<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>↑ sensitivity to cisplatin and selected anticancer agents (model-dependent)</td>
<td>Insufficient evidence</td>
<td>Potential reversal of treatment resistance</td>
<td>Recent TNBC work links cisplatin sensitization to direct ENO1 targeting, ↓ glycolysis/lactylation and impaired resistance-associated DNA repair. Primarily preclinical evidence.</td>
</tr>
<tr>
<td>13</td>
<td>Clinical Translation Constraint</td>
<td>High experimental concentrations frequently required</td>
<td>Hepatotoxicity and neurotoxicity possible at excessive exposure</td>
<td>Limits systemic therapeutic window</td>
<td>Low oral bioavailability, uncertain human tumor exposure, formulation dependence and toxicity remain major barriers. Clinical findings with Compound Kushen Injection cannot be attributed specifically to matrine.</td>
</tr>
</tbody>
</table>
<br><br>
<hr>
<br><br>
<p><b>Alzheimer's disease relevance:</b> Matrine has meaningful but entirely preclinical evidence in Alzheimer’s disease models. Reported effects include inhibition of Aβ aggregation, interference with the RAGE/Aβ axis, reduction of Aβ deposition, suppression of microglial activation and NADPH-oxidase-derived oxidative stress, reduction of inflammatory cytokines, and improvement of learning and memory in rodent models. No convincing human therapeutic evidence establishes matrine as an AD treatment.</p>
<p><b>Clinical evidence status:</b> Preclinical only. The strongest evidence consists of cellular Aβ studies and multiple rodent AD models; clinical efficacy, dosing, long-term neurological safety and achievable CNS exposure remain undetermined.</p>
<h3>Matrine in Alzheimer's Disease</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Aβ Aggregation</td>
<td>↓ Aβ42 aggregation; ↑ disaggregation of immature oligomers</td>
<td>↓ amyloid-associated cytotoxicity</td>
<td>Demonstrated in biochemical/cellular systems and supported by reduced Aβ deposition in animal models.</td>
</tr>
<tr>
<td>2</td>
<td>RAGE / Aβ Axis</td>
<td>↓ RAGE/Aβ signaling</td>
<td>↓ Aβ-mediated neuronal injury and inflammation</td>
<td>A prominent mechanism in an AD transgenic-mouse study.</td>
</tr>
<tr>
<td>3</td>
<td>Microglial Activation / Neuroinflammation</td>
<td>↓ microglial activation; ↓ TNF-α; ↓ IL-1β; ↓ IL-6</td>
<td>↓ neuroinflammation</td>
<td>Associated with improved learning and memory in Aβ-induced mouse models.</td>
</tr>
<tr>
<td>4</td>
<td>NADPH Oxidase / ROS</td>
<td>↓ gp91phox; ↓ p47phox; ↓ ROS</td>
<td>↓ oxidative neuronal stress</td>
<td>Notable contrast with the pro-oxidant ROS response reported in several cancer-cell models.</td>
</tr>
<tr>
<td>5</td>
<td>Th17 / Treg Balance</td>
<td>↓ IL-17A; ↓ IL-23; ↓ RORγt; ↑ TGF-β; ↑ IL-35; ↑ Foxp3</td>
<td>Immune modulation</td>
<td>Reported in an Aβ1-42 rat model together with improved cognitive performance.</td>
</tr>
<tr>
<td>6</td>
<td>Clinical Translation Constraint</td>
<td>Human efficacy unknown</td>
<td>Preclinical evidence only</td>
<td>CNS exposure, effective human dose, chronic safety and clinical benefit have not been established.</td>
</tr>
</tbody>
</table>